J. Sgrignani

Characterization of a novel humanized heavy chain antibody targeting endogenous retroviruses with anti-lymphoma activity

This study identifies HERV-K as a therapeutic target in DLBCL, develops a humanized nanobody with anti-lymphoma activity, and shows its potential through antibody-dependent cytotoxicity.

PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine

This paper identifies two resistance mechanisms to the CD37-targeting ADC naratuximab emtansine in lymphoma cell lines and suggests combination therapies to overcome resistance.

Mitochondrial DNA released by senescent cells triggers immunosuppression in cancer

This study shows that mtDNA released by senescent cells triggers immunosuppression via PMN-MDSCs, and inhibiting this pathway enhances therapy-induced senescence in cancer.

Human neutralizing antibodies to cold linear epitopes and to subdomain 1 of SARS-CoV-2

The paper identifies broadly cross-reactive neutralizing antibodies against SARS-CoV-2 variants using coldspot-guided antibody discovery.

Anti-chemokine antibodies after SARS-CoV-2 infection correlate with favorable disease course

The paper finds that anti-chemokine antibodies after SARS-CoV-2 infection correlate with favorable disease outcomes and predict absence of long COVID symptoms.

Systematic development of peptide inhibitors targeting the CXCL12/HMGB1 interaction

This study identifies a peptide inhibitor (HBP08) that disrupts the CXCL12/HMGB1 heterocomplex with high affinity, offering potential for treating chronic inflammatory diseases.

Oxidation state dependent conformational changes of HMGB1 regulates the formation of the CXCL12/HMGB1 heterocomplex

This study shows that the redox state of HMGB1 affects its conformation, enabling complex formation with CXCL12, which enhances leukocyte recruitment via CXCR4.